Patents Assigned to Universitat Zürich
-
Publication number: 20210204961Abstract: An occlusion device (20) includes a compliant balloon (5) including an inflation port (3) for filling and unfilling a fluid into and from a balloon chamber (26). A distal tip element (10) and a proximal base element (4) are disposed at distal and proximal sides (28B, 28A) of the balloon (5), respectively. An elongate actuating element (9) is disposed longitudinally slidable in a balloon lumen (6) forming a longitudinal passage (27) from the proximal side (28A) to the distal side (28B) of the balloon (5), connected to the distal tip element (10), and longitudinally moveable with respect to the proximal base element (4) so as to set a distance between the distal tip element (100 and the proximal base element (4). A locking mechanism (2) is configured to maintain, between the distal tip element (10) and the proximal base element (4), the distance set using the elongate actuating element (9).Type: ApplicationFiled: March 19, 2021Publication date: July 8, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Francesco MAISANO, Andrea GUIDOTTI, Idan TOBIS, David ZARBATANY
-
Publication number: 20210162019Abstract: The disclosure relates to the treatment, diagnosis and/or prevention of multiple sclerosis (MS) by using an immunodominant protein or peptide. More particular the invention relates to the field of antigen specific immunotherapies, such as the induction of tolerance.Type: ApplicationFiled: June 28, 2019Publication date: June 3, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Mireia SOSPEDRA RAMOS, Roland MARTIN
-
Publication number: 20210137040Abstract: The present invention provides an improved Helminthosporium turcicum-resistant plant, in particular a maize plant which comprises a polynucleotide with one or more resistance-conferring genes, for example on a truncated chromosome fragment from the accession Pepitilla, as well as a cell, a tissue, a part, grain and seeds thereof, an isolated polynucleotide which comprises one or more resistance-conferring genes against Helminthosporium turcicum, a vector, a transgenic plant cell and a transgenic plant containing this polynucleotide. Furthermore, the invention encompasses suitable markers and their use in introducing resistance or the transgene into a plant, as well as the identification of improved maize plants which comprise a truncated chromosome fragment.Type: ApplicationFiled: December 16, 2020Publication date: May 13, 2021Applicants: KWS SAAT SE & CO. KGAA, UNIVERSITÄT ZÜRICHInventors: Milena OUZUNOVA, Daniela SCHEUERMANN, Beat KELLER, Simon KRATTINGER, Thomas WICKER, Gerhard HERREN, Severine HURNI, Bettina KESSEL, Thomas PRESTERL, Carsten KNAAK
-
Publication number: 20210140948Abstract: The invention relates to a method for multiplex staining of a biological sample involving the use of a buffer combination of blocking buffer, imaging buffer and elution buffer that allows for multiple staining rounds of biological samples. The blocking buffer comprises a compound that is capable of binding to hydrophobic binding sites non-specifically and a sulfhydryl-reactive compound. The imaging buffer is at neutral pH and comprises a radical scavenger, and the elution buffer is at pH lower than 4 and comprises a buffering component, a reducing agent and at least one compound disrupting hydrogen bonds. The invention further relates to buffers used in the practice of the method of the invention, and to a kit containing these buffers.Type: ApplicationFiled: April 24, 2019Publication date: May 13, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Gabriele GUT, Lucas PELKMANS, Markus HERRMANN
-
Publication number: 20210070851Abstract: Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.Type: ApplicationFiled: February 22, 2019Publication date: March 11, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Sonia TUGUES, Burkhard BECHER
-
Publication number: 20210071198Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP). matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerise II or RNA polymerase III.Type: ApplicationFiled: April 29, 2020Publication date: March 11, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Publication number: 20210060208Abstract: The present invention concerns a tissue-engineered medical device, as well as a method for the production said medical device, comprising the following steps: providing a polymer scaffold comprising a mesh comprising polyglycolic acid, and a coating comprising poly-4-hydroxybutyrate; application of a cell suspension containing preferably human cells to the polymer scaffold; placement of the seeded polymer scaffold in a bioreactor and mechanical stimulation by exposure to a pulsatile flux of incremental intensity, thereby forming an extracellular matrix; mounting of the graft on a conduit stabilizer and incubation in cell culture medium; decellularisation of the graft in a washing solution; nuclease treatment of the graft; and rinsing of graft. The invention further comprises and various steps of quality control of the tissue-engineered medical device.Type: ApplicationFiled: August 28, 2018Publication date: March 4, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Simon-Philipp HOERSTRUP, Maximilian Y. EMMERT, Frank BAAIJENS, Anita DRIESSEN-MOL
-
Patent number: 10912497Abstract: A device for detecting and evaluating movements of a user comprises a processing unit, a data memory, a sensor unit with at least one biometric sensor, and a fastening device for fastening the sensor unit on an arm of the user. The processing unit is configured to detect movement data from movement signals generated by the sensor unit and to store the movement data in the data memory. The device further comprises an evaluation module with which secondary movement data, which represent passive arm movements of the user, are filterable out of the movement data. The device enables the detection and evaluation of movements of an arm of the user in an efficient way.Type: GrantFiled: August 23, 2016Date of Patent: February 9, 2021Assignees: TYROMOTION GMBH, ETH ZÜRICH, UNIVERSITÄT ZÜRICH, ZÜRCHER HOCHSCHULE DER KÜNSTEInventors: Karmen Franinovic, Dinis Meier, Samuel Bauer, Roger Gassert, Yeongmi Kim, Kaspar Leuenberger, Andreas Luft, Jeremia Held
-
Patent number: 10897862Abstract: The present invention provides an improved Helminthosporium turcicum-resistant plant, in particular a maize plant which comprises a polynucleotide with one or more resistance-conferring genes, for example on a truncated chromosome fragment from the accession Pepitilla, as well as a cell, a tissue, a part, grain and seeds thereof, an isolated polynucleotide which comprises one or more resistance-conferring genes against Helminthosporium turcicum, a vector, a transgenic plant cell and a transgenic plant containing this polynucleotide. Furthermore, the invention encompasses suitable markers and their use in introducing resistance or the transgene into a plant, as well as the identification of improved maize plants which comprise a truncated chromosome fragment.Type: GrantFiled: September 3, 2014Date of Patent: January 26, 2021Assignees: KWS SAAT SE & CO. KGAA, UNIVERSITÄT ZÜRICHInventors: Milena Ouzunova, Daniela Scheuermann, Beat Keller, Simon Krattinger, Thomas Wicker, Gerhard Herren, Severine Hurni, Bettina Kessel, Thomas Presterl, Carsten Knaak
-
Patent number: 10894828Abstract: The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.Type: GrantFiled: July 10, 2015Date of Patent: January 19, 2021Assignee: Universität ZürichInventors: Onur Boyman, Natalia Arenas-Ramirez, Chao Zou
-
Patent number: 10889643Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.Type: GrantFiled: January 11, 2017Date of Patent: January 12, 2021Assignee: Universität ZürichInventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
-
Publication number: 20200399401Abstract: The present invention relates to the field of antibodies useful in therapy and diagnosis. It specifically discloses bioconjugates comprising one or more antibodies bound to functionalized, magnetic nanoparticles. These bioconjugates are useful in cancer therapy, particularly for removing circulating tumor cells. The invention further pertains to specific functionalized, magnetic nanoparticles and to the manufacturing of such bioconjugates and such functionalized, magnetic nanoparticles.Type: ApplicationFiled: February 25, 2019Publication date: December 24, 2020Applicants: Universität Zürich, ETH ZurichInventors: Antoine Florent Herzog, Wendelin Jan Stark, Martin Zeltner, Beatrice Beck-Schimmer, Anja Zabel
-
Patent number: 10870846Abstract: The invention relates to a method for selecting a sequence set from a library of expressed nucleic acid sequences, wherein cells are provided, each cell comprises an expressed nucleic acid sequence expressed as a target protein. The cells are encapsulated by treating them with a cationic polysaccharide and subsequently treating them with an anionic polysaccharide, yielding encapsulated cells, perforating the membrane of the encapsulated cells, yielding solubilized compartments, contacting them with a ligand to said target protein, the ligand bearing a detectable label, and selecting a subset of solubilized compartments as a function of detectable label and isolating the expressed nucleic acid sequences from the selection as a selected sequence set.Type: GrantFiled: January 9, 2013Date of Patent: December 22, 2020Assignee: Universität ZürichInventors: Daniel Scott, Andreas Plückthun
-
Patent number: 10839898Abstract: A differential memristive circuit includes a normaliser; a first memristor connected between first top and bottom nodes, the first memristive element having a first adjustable resistance value; a first switch connected between the first bottom node and the normaliser; a second memristor connected between a second top node and a second bottom node the second memristor having a second adjustable resistance value; a second switch connected between the second bottom node and the normaliser; and a set of voltage sources that generate voltages greater than 0V. The set of voltage sources generate a first voltage value across the first memristor and a second voltage value across the second memristor. A first output signal depends on the first adjustable resistance value, while a second output signal depends on the second adjustable resistance value. A memristive circuit net output signal is obtained as the difference between the first and second output signals.Type: GrantFiled: July 22, 2018Date of Patent: November 17, 2020Assignee: UNIVERSITÄT ZÜRICHInventors: Giacomo Indiveri, Manu Vijayagopalan Nair
-
Patent number: 10835600Abstract: The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat. Furthermore, the present invention relates to compositions comprising a virus-like particle (VLP) and at least one Fel d1 protein. The compositions of the invention induce efficient immune responses, in particular antibody responses, in cats and are useful for the treatment and/or prevention of cat allergy.Type: GrantFiled: September 7, 2016Date of Patent: November 17, 2020Assignee: UNIVERSITÄT ZÜRICHInventors: Martin Bachmann, Gary Jennings, Thomas Kündig, Gabriela Senti, Franziska Zabel
-
Publication number: 20200330623Abstract: Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ligand is coordinated to the transition metal and the radioisotope to link the transition metal and the radioisotope and pendent ligands are coordinated to each of the transition metal and the radioisotope to stabilise the complex. The multinuclear complexes may include a radioisotope or radioelement that can be detected by medical equipment and may find use in therapy and/or the diagnosis of disease in patients.Type: ApplicationFiled: December 21, 2018Publication date: October 22, 2020Applicants: UNIVERSITY OF THE FREE STATE, UNIVERSITÄT ZÜRICHInventors: Andreas ROODT, Roger Ariel ALBERTO, Angelo FREI, Petrus Pennie MOKOLOKOLO, Robin Kim BOLLINGER, Alice BRINK, Dumisani Vincent KAMA
-
Publication number: 20200281724Abstract: The invention relates to an osteoconductive graft comprising a biocompatible material that is interspersed with a network of non-overlapping pores connected by channels, and wherein the pores are characterized by a pore diameter of 0.6 mm to 1.4 mm, the channels are characterized by a channel diameter of 0.5 mm to 1.3 mm, the channel diameter is smaller than the pore diameter and the pores are aligned in one, two or three spatial axes at regularly spaced intervals.Type: ApplicationFiled: September 19, 2018Publication date: September 10, 2020Applicant: UNIVERSITÄT ZÜRICHInventor: Franz WEBER
-
Publication number: 20200275935Abstract: An occluder device (20) for occluding a cardiovascular defect or a gap between a medical device and adjacent body tissue comprises:—a compliant balloon (5) defining a fluid-tight balloon chamber and provided with a balloon channel (7) forming a longitudinal passage from a proximal side (B2) to a distal side (B1) of the balloon; —a tip element (10) disposed at the distal side of the balloon, a base element (4) disposed at the proximal side of the balloon, and connecting means comprising at least one connecting stmt (9) attached to the tip element and to the base element, the tip element and the base element each having a guide opening (105a, 105b) substantially coaxial to the balloon channel (7) for slidingly receiving therein a guidewire (106) for the device; —elongated actuating means disposed longitudinally slidable in the balloon channel (7), releasably connectable to the tip element (10), and longitudinally slidable with respect to the base element (4); —locking means (2, 13) for maintaining a predeterminType: ApplicationFiled: September 23, 2018Publication date: September 3, 2020Applicant: UNIVERSITÄT ZÜRICHInventors: Francesco MAISANO, Andrea GUIDOTTI, Idan TOBIS, David ZARBATANY
-
Publication number: 20200234762Abstract: A differential memristive circuit includes a normaliser; a first memristor connected between first top and bottom nodes, the first memristive element having a first adjustable resistance value; a first switch connected between the first bottom node and the normaliser; a second memristor connected between a second top node and a second bottom node the second memristor having a second adjustable resistance value; a second switch connected between the second bottom node and the normaliser; and a set of voltage sources that generate voltages greater than 0V. The set of voltage sources generate a first voltage value across the first memristor and a second voltage value across the second memristor. A first output signal depends on the first adjustable resistance value, while a second output signal depends on the second adjustable resistance value. A memristive circuit net output signal is obtained as the difference between the first and second output signals.Type: ApplicationFiled: July 22, 2018Publication date: July 23, 2020Applicant: UNIVERSITÄT ZÜRICHInventors: Giacomo INDIVERI, Manu Vijayagopalan NAIR
-
Publication number: 20200219267Abstract: The invention relates a method for generating a motion-corrected image for visual-inertial odometry comprising an event camera rigidly connected to an inertial measurement unit (IMU), wherein the event camera comprises pixels arranged in an image plane that are configured to output events in presence of brightness changes in a scene at the time they occur, wherein each event comprises the time at which it is recorded and a position of the respective pixel that detected the brightness change, the method comprising the steps of: Acquiring at least one set of events (S), wherein the at least one set (S) comprises a plurality of subsequent events (e); Acquiring IMU data (D) for the duration of the at least one set (S); Generating a motion-corrected image from the at least one set (S) of events (e), wherein the motion-corrected image is obtained by assigning the position (xj) of each event (ej) recorded at its corresponding event time (tj) at an estimated event camera pose (Ttj) to an adjusted event position (x?j)Type: ApplicationFiled: September 3, 2018Publication date: July 9, 2020Applicant: UNIVERSITÄT ZÜRICHInventors: Henri REBECQ, Davide SCARAMUZZA